��������

Shuai Li has extensive work experience in various roles and industries. From 2014 to 2017, they worked as a Postdoctoral fellow and Research Associate at the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, where they focused on biotech, gene therapy, and immunotherapy of cancer. In 2016, they joined Beijing BW Invest as an Investment Director, a position they held until 2018. In 2018, they joined WI Harper Group as a Senior Associate and was later promoted to Vice President in January 2020.

Shuai Li attended Peking University from 2009 to 2014, where they obtained a Doctorate degree in Molecular Biology and Tumor Biology. Additionally, they pursued a Doctor of Philosophy (Ph.D.) degree in Tumor Biology at Peking University Health Science Center during the same time period.